Amgen Shares Fall as Investors Assess Novartis Lp(a) Trial Result and BMO Downgrade
Amgen Shares Fall as Investors Assess Novartis Lp(a) Trial Result and BMO Downgrade Yahoo Finance
Covered in this story
What has happened since
- Amgen is up 5.1% since this was published, 29 days ago.
- Novartis is up 7.4% since this was published, 29 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Amgen
- Cantor Fitzgerald: $403 → $400 by Oct 2027 · Neutral via Investing.com
- Scotiabank: $403 → $500 by Oct 2027 via AD HOC NEWS
- Scotiabank: $424 → $500 by Sep 2027 · Sector Outperform via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 49 stories mentioning Amgen, the earliest published 14 Jul 2026.
Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.